Long lesions (&ge; 15 cm), total occlusions, and in-stent restenosis represent a unique treatment challenge in peripheral vascular disease. IN.PACT Global study is a prospective, multicenter, single arm designed to evaluate the safety and efficacy of IN.PACT&reg; ADMIRAL&reg; drug eluting balloon for the treatment of superficial femoral and popliteal arteries in a real-world population. A<a href="https://solaci.org/en/2015/06/24/in-pact-global-study-pharmacological-balloon-in-long-lesions-of-the-superficial-femoral-artery-sfa/" title="Read more" >...</a>

Fundamentos: Diversos estudos para avalia&ccedil;&atilde;o de seguran&ccedil;a e efic&aacute;cia dos stents farmacol&oacute;gicos com pol&iacute;meros biodegrad&aacute;veis est&atilde;o em andamento, sobretudo na vig&ecirc;ncia de infarto do mioc&aacute;rdio com supra-desnivelamento do segmento ST (STEMIs). Objetivos: Confirmar a seguran&ccedil;a e efic&aacute;cia do stent farmacol&oacute;gico com pol&iacute;mero bioabsorv&iacute;vel Ultimaster em STEMIs. M&eacute;todos: Estudo multic&ecirc;ntrico, cego, prospectivo, randomizado (3:1 Ultimaster DES<a href="https://solaci.org/en/2015/06/24/estudo-master-demonstra-a-seguranca-e-eficacia-de-polimeros-biodegradaveis-de-stents-farmacologicos-em-relacao-aos-stents-convencionais-em-pacientes-com-stemis-2/" title="Read more" >...</a>

Article The TAXUS Libert&eacute; Post Approval study included patients treated with TAXUS paclitaxel DES receiving prasugrel for 12 to 30 months. Primary end point was a combination of death, infarction or stroke that resulted in 3.7% after 30 months vs. 8.8% after 12 months of prasugrel administration (p&lt;0.001). Death and stroke rates were similar between<a href="https://solaci.org/en/2015/06/24/reduction-of-ischemic-events-after-30-months-of-prasugrel-following-taxus-stent-implantation/" title="Read more" >...</a>

This prospective, multicenter, randomized trial compared the paclitaxel-eluting balloon versus everolimus-eluting stent to treat patients with in-stent restenosis. 309 patients were included in total (154 received the drug-eluting balloon, and 155 received the everolimus-eluting stent). There were no differences in the characteristics of both groups. At one year the rate of cardiac death, myocardial infarction<a href="https://solaci.org/en/2015/06/24/ribs-iv-drug-eluting-balloon-versus-everolimus-eluting-stent-on-in-stent-restenosis/" title="Read more" >...</a>

The paclitaxel-eluting balloon could be an option to minimize the side branch restenosis in coronary bifurcations. In this study, the angiographic and clinical outcomes of paclitaxel-eluting balloon plus conventional stent versus DES in bifurcation &#8220;de novo&#8221; lesion were compared.&nbsp; This multicenter study included 108 patients randomized to sequential dilation of the main branch and the<a href="https://solaci.org/en/2015/06/24/babilon-pharmacological-balloon-to-treat-the-lateral-branch-in-coronary-bifurcations/" title="Read more" >...</a>

The trial included 1,900 patients followed for at least 2 years, (mean 3.8 years), randomized 1:1 to pharmacological angioplasty stents, (sirolimus or paclitaxel at surgeon discretion), or CABG. We excluded acute coronary syndromes and left coronary trunk injury. The primary endpoint was death, myocardial infarction or stroke and the secondary main was the sum of<a href="https://solaci.org/en/2015/06/24/freedom-trial-cabg-versus-angioplasty-treatment-for-diabetic-patients-with-multivessel-disease/" title="Read more" >...</a>

ISAR-DESIRE 3 did not show that paclitaxel-eluting balloon may be useful for treating restenosis of a sirolimus&#8211;eluting stent. This study tests the safety and efficacy of a paclitaxel-eluting balloon versus a paclitaxel-eluting stent in cases of in-stent drug-eluting restenosis. We included 220 patients with in-stent restenosis of a drug-eluting stent ball randomized at a 1:1<a href="https://solaci.org/en/2015/06/24/treatment-of-in-stent-restenosis-with-drug-eluting-balloon/" title="Read more" >...</a>

This study is still in progress and includes patients using SYNTAX II score based on functional invasive evaluation with iFR / FFR and performing angioplasty guided by IVUS using the biodegradable polymer everolimus eluting stent. The study seeks to prove superiority versus the first generation paclitaxel-eluting stent and non-inferiority versus surgery using historical data. We<a href="https://solaci.org/en/2015/06/24/syntax-ii-multiple-vessels-using-ifr-ffr-and-ivus/" title="Read more" >...</a>

This prospective multicenter study randomized 476 patients 2:1 to paclitaxel eluting balloon versus conventional balloon for femoropopliteal region lesions with the primary objective of assessing death, free amputationsurvival and reintervention at 6 months. At 6 months follow-up a higher rate of restenosis with conventional balloon was observed.These are preliminary results and we must wait for<a href="https://solaci.org/en/2015/06/24/levant-2-initial-results-from-the-new-drug-eluting-balloon-for-femoropopliteal-lesions/" title="Read more" >...</a>

The ideal therapy for treating in-stent restenosis continues to be debated . The pharmacological balloons showed good results in this context, but no direct comparisons available of pharmacological balloonsversus second-generation DES.This prospective, multicenter randomized 189 patients with in-stent restenosis of conventional stents receiving pharmacological balloon or everolimusDES.The primary endpoint was angiographicat 9 months spotting a<a href="https://solaci.org/en/2015/06/24/ribs-v-pharmacological-balloon-vs-second-generation-drug-eluting-stent-in-the-treatment-of-bms-restenosis/" title="Read more" >...</a>